Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge

Journal of Infectious Diseases

Volumn 180, Issue 3, 1999, Pages 708-713

  Fisher, Randall G ^a,c   Johnson, Joyce E ^a   Dillon, Susan B ^d   Parker, Robert A ^b   Graham, Barney S ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Division of Infectious Diseases ^*

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RSHZ 19; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNOPROPHYLAXIS; INTRAPERITONEAL DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT INFECTION; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY FORMATION; CHILD; FEMALE; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA-CHAINS; INFANT; LUNG; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; TUMOR CELLS, CULTURED; VIRUS REPLICATION; WEIGHT LOSS;

EID: 0032825526     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314965     Document Type: Article

References (18)

1. 1. Gruber WC, Wilson SZ, Throop BJ, Wyde PR. Immunoglobulin administration and ribavirin therapy: efficacy in respiratory syncytial virus infection of the cotton rat. Pediatr Res 1987;21:270-4.
2. 2. Taylor G, Stott EJ, Bew M, et al. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology 1984;52:137-42.
3. 3. Graham BS, Davis TH, Tang YW, Bunton LA, Gruber WC. Immunoprophylaxis and immunotherapy of respiratory syncytial virus-infected mice with RSV-specific immune serum. Pediatr Res 1993;34:167-72.
4. 4. Groothius JR, Simoes EAF, Levin MJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993;329:1524-9.
5. 5. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
6. 6. Graham BS, Perkins MD, Wright PF, Karzon DT. Primary respiratory syncytial virus infection in mice. J Med Virol 1988;26:153-62.
7. 7. Jones PT, Dear PH, Foote J, Neuberger M, Winter G. Replacing the complementarity determining regions in a human antibody with those from a mouse. Nature 1986;321:522-5.
8. 8. Davis CB, Hepburn TW, Urbanski JJ, et al. Preclinical pharmacokinetic evaluation of the respiratory syncytial virus-specific reshaped human monoclonal antibody RSHZ19. Drug Metab Dispos 1995;23:1028-36.
9. 9. Graham BS, Bunton LA, Wright PF, Karzon DT. Reinfection of mice with respiratory syncytial virus. J Med Virol 1991;34:7-13.
10. 10. Murphy BR, Prince GA, Collins PL, Hildreth SW, Paradiso PR. Effect of passive antibody on the immune response of cotton rats to purified F and G glycoprotein of respiratory syncytial virus. Vaccine 1991;9:185-9.
11. 11. Hemming VG, Prince GA, Horswood RL, et al. Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model. J Infect Dis 1985;152:1083-6.
12. 12. Gadd SJ, Brogan MP, Ashman LK. Specificity of the passive antibody-induced suppression of the humoral immune response of mice to surface antigens on human cells. Immunology 1985;54:223-31.
13. 13. Malley R, DeVincenzo J, Ramilo O, et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F Protein. J Infect Dis 1998;178:1555-61.
14. 14. Small PA Jr, Waldman RH, Bruno JC, Gifford GE. Influenza infection in ferrets: role of serum antibody in protection and recovery. Infect Immun 1976;13:417-24.
15. 15. Loosli CG, Hamre D, Berlin BS. Airborne influenza virus A infection infections in immunized animals. Trans Assoc Am Phys 1953;66:222-30.
16. 16. Pincus CS, Nussenzweig V. Passive antibody may simultaneously suppress and stimulate antibody formation against different portions of a protein molecule, Nature 1969;222:594-6.
17. 17. Urquhart GE, Crawford RJ, Wallace J. Trial of high-titre human rubella immunoglobulin. Br Med J 1978;2:1331-2.
18. 18. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176:1215-24.